Retatrutide is an investigational once-weekly medication being studied for its potential effects on weight and metabolic health. Developed by Eli Lilly, it works through a unique triple-action mechanism that targets three different hormone receptors at once.
As of June 2026, Retatrutide has not been approved by the FDA or any regulatory agency. It is available only inside clinical trials. This website exists to provide clear, trustworthy educational information — with a particular focus on helping readers understand dosing considerations, including the context around 10 mg that appears in some research discussions and titration schedules.
What You’ll Find Here
- Straightforward explanations of how Retatrutide works
- Detailed yet accessible summaries of the latest Phase 3 trial results
- Focused discussion on dosing, including the 10 mg context within published data
- Balanced information on safety and side effects observed in trials
- Clear warnings about legal status and risks of unapproved products
Everything is written for general readers who want accurate information without unnecessary complexity.
Important Note
This is not medical advice. Retatrutide is still under investigation. The decision to participate in a clinical trial or use any medication must be made with a qualified healthcare provider.
Quick Overview Box
- Status (June 2026): Investigational – not approved or available outside trials
- Administration: Once-weekly injection with gradual dose increases
- Key Phase 3 Result: Average weight loss up to 28.3% at the highest studied dose over 80 weeks (TRIUMPH-1)
- Focus of This Site: Educational clarity around dosing, including discussions near the 10 mg level
Retatrutide Dosing Guide: Understanding the Context Around 10 mg
One of the most common questions readers have is about specific dose levels, particularly around 10 mg. This page explains what is known from the clinical trials and how the 10 mg context fits into the bigger picture.
Doses Studied in Pivotal Phase 3 Trials
The main TRIUMPH-1 trial evaluated three target doses reached through gradual escalation:
- 4 mg
- 9 mg
- 12 mg
All were given once weekly by subcutaneous injection. Participants started at a low dose (commonly 2 mg) and increased every four weeks as tolerated. This slow titration approach was used to help reduce side effects.
Where Does 10 mg Fit?
While the large Phase 3 studies used the discrete targets of 4 mg, 9 mg, and 12 mg, titration schedules naturally include several intermediate steps. Some extended protocols and earlier phase explorations have referenced doses in the broader 8–12 mg range.
In certain research discussions and clinical commentary, a level near 10 mg is sometimes considered as a potential individualized target or maintenance option — for example, for people who respond well to lower steps but find the full 12 mg dose less tolerable.
It is important to be clear: there is no large pivotal trial with a primary 10 mg target arm that has the same robust published data as the 9 mg and 12 mg groups. Any specific dose decision outside a clinical trial setting would be off-label and carries unknown risks.
Key Principles from the Trials
- Start low and go slow — this was the consistent strategy.
- Dose increases occurred every four weeks based on how well participants tolerated the medication.
- Higher doses generally showed greater average weight loss, but also came with a higher chance of gastrointestinal side effects.
- Individual responses varied considerably.
Practical Educational Takeaway
The published data give us the clearest picture at the studied targets of 4 mg, 9 mg, and 12 mg. Discussions around 10 mg usually arise in the context of flexible titration or personalized approaches within research settings. Only qualified investigators in trials (or licensed prescribers in the future, if approved) can make dosing decisions.
Table – Summary of Studied Target Doses (TRIUMPH-1, ~80 weeks)
Data synthesized from publicly released Eli Lilly Phase 3 topline results (May 2026).
This table is for educational understanding only.
Strong reminder: This page is for educational purposes. It does not constitute dosing advice. Retatrutide is investigational.
Critical Legal & Safety Warnings
Important Warnings: Legal Status of Retatrutide and Risks of Unapproved Products
Important Warnings: Legal Status & Safety Risks
Current Legal Status (June 2026)
Retatrutide is an investigational medication. It has not been approved by the FDA or any other regulatory agency. It is legally available only to participants enrolled in Eli Lilly-sponsored clinical trials.
It is not available by prescription anywhere.
Risks of Unapproved or Compounded Products
Any product being sold online, in clinics, or elsewhere as “Retatrutide”, “Retatrutide 10mg”, or similar is not legitimate. These products:
- Have not been tested for safety, purity, or correct dosing in the same rigorous way as clinical trial material.
- May be contaminated, under-dosed, over-dosed, or completely fake.
- Carry serious and potentially life-threatening health risks.
- Are being sold illegally.
The only safe and legal way to access Retatrutide at this time is through participation in an official clinical trial (when eligible).
Our Strong Recommendation
Do not purchase or use any product claiming to contain Retatrutide. If you are interested in clinical research, visit ClinicalTrials.gov and search for Retatrutide (LY3437943) trials, or speak with your doctor about whether any trial might be suitable for you.
This website exists to educate, not to facilitate access to unapproved medications.
Last reviewed: June 2026